Publications by authors named "Krista Fager"

Claim this Profile
I
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Feng Roger Luo, Yu Chen Barrett, Zheng Yang, Amy Camuso, Kelly McGlinchey, Krista Fager

Cancer Chemother Pharmacol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Feng R Luo, Zheng Yang, Amy Camuso, Richard Smykla, Kelly McGlinchey, Krista Fager

Clin Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.
Robert Wild, Krista Fager, Christine Flefleh, David Kan, Ivan Inigo

Mol Cancer Ther· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.
Feng R Luo, Zheng Yang, Huijin Dong, Amy Camuso, Kelly McGlinchey, Krista Fager

Clin Cancer Res· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
Louis J Lombardo, Amy Camuso, John Clark, Krista Fager, Johnni Gullo-Brown

Bioorg Med Chem Lett· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis